Ignite Creation Date:
2024-05-05 @ 11:49 AM
Last Modification Date:
2024-10-26 @ 9:14 AM
Study NCT ID:
NCT00146289
Status:
COMPLETED
Last Update Posted:
2013-11-01
First Post:
2005-09-02
Brief Title:
The Primary Objective of This Study is to Determine Whether MICARDIS Improves Insulin Sensitivity in Overweight or Obese Non-diabetic Normotensive Subjects
Sponsor:
Boehringer Ingelheim
Organization:
Boehringer Ingelheim
Study Overview
Official Title:
A Randomised DB Placebo-controlled Parallel Group 16-wk MICARDIS 160mg Tab Proof-of-concept Evaluating Insulin Sensitivity in Overweight or Obese Non-diabetic Normotensive Using the OGTT With a Clamp Sub-group
Status:
COMPLETED
Status Verified Date:
2013-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The primary objective of this study is to determine whether MICARDIS improves insulin sensitivity in overweight or obese non-diabetic normotensive subjects
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None